2008 Expectations: Ongoing implementation of programs already in place to support our five key strategic initiatives is expected to enable the Company to meet its 7% long-term organic growth goal for 2008. A modest additional carryover benefit in Q1 2008 from the February 2007 acquisition and currency benefits could add 3% more to reported growth rates if currency exchange rates remain at December 31, 2007 levels.
The activities that drove above-target organic sales growth in Research Specialties over the past six quarters are expected to continue to drive growth of 7% to 8% for the year, well ahead of its 6% long-term goal.
Research Essentials is also expected to continue to meet or beat its long-term organic growth goal of 4%, with growth of 4% to 5% forecast for this year. Continued progress in exploiting sales opportunities in CAPLA markets by stocking larger local quantities of inventory, expanding relationships with local customers and more closely coordinated marketing programs aimed at research customers in all geographic areas should aid both Research Essentials and Research Specialties results for the year.
Research Biotech is expected to continue its momentum towards reaching its 10% long-term organic growth potential by delivering organic sales growth of 7% to 8% in 2008, roughly half way between its most recent annual performance and its long-term growth goal. This unit should continue to benefit from the increased sales efforts launched early in 2007, the ongoing addition of innovative products to its broad product and service offering, the listing of many of our biotechnology products in new public scientific search databases, the availability of new tools such as "Your Favorite Gene" that streamline customers' web search activities and the continued expansion of products available through internal and collaborative R&D efforts under licenses from and agreements with Sangamo BioSciences.
|SOURCE Sigma-Aldrich Corporation|
Copyright©2008 PR Newswire.
All rights reserved